SCHEMBL23988520

SCHEMBL23988520

COc1ccc2[nH]c(S(=O)(=O)Cc3nccc(OC)c3OC)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.56
ATP4A P20648 7/20 0.43
ATP4B P51164 7/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SLC22A2 O15244 1/20 0.43
DDAH1 O94760 1/20 0.43
LMNA P02545 1/20 0.43
ABCB1 P08183 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
ADRA1A P35348 1/20 0.43
FASN P49327 1/20 0.43
SLC47A2 Q86VL8 1/20 0.43
SLC47A1 Q96FL8 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
CA2 P00918 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988474 0.90 RUNX1 (0.51) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL30102856 0.90 ATP4A (0.56) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL538298 0.90 ATP4A (0.56) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988406 0.89 CYP2C9 (0.58) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988415 0.86 ALDH1A1 (0.51) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988416 0.84 CYP2C9 (0.42) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL15475057 0.82 ATP4A (0.66) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988519 0.82 CYP2C9 (0.53) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988596 0.81 CYP2C9 (0.52) CYP2C9ATP4AATP4BALDH1A1MAPT
SCHEMBL23988512 0.80 ATP4A (0.56) CYP2C9ATP4AATP4BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202796-A1 CXCL10 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-06-30 US disclosed
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202796-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 CYP2C9 4152/4885ATP4A 4581/4885ATP4B 4629/4885
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 CYP2C9 4152/4885ATP4A 4581/4885ATP4B 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.